NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think the only way they would separate a continuance group from a halt is to use the pseudoprogression group which is in the same trial but analyzed separately. See some of my posts using search keywords mesenchymal and or classic. The pseudoprogression group may largely be composed of mesenchymal. Does this mean the separately analyzed group still has their own control randomization and primary endpoint? Maybe. If so, one could envision where the pseudoprgression group is halted first, while the main group is continued. Or visa versa.

Because they were separated in the first place, such different outcomes would not lessen powering in whichever group is hypothetically left to continue.

The additional good news is that IMHO the main group likely has a robust population of mesenchymal and classis tumors, so it is likely to respond to dcvax-l as well. So if they were halted at different times for efficacy, I would not bet on which group comes in first.